Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AKBA

AKBA - Akebia Therapeutics Inc Stock Price, Fair Value and News

$1.47+0.07 (+5.00%)
Market Closed

34/100

AKBA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

AKBA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AKBA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKBA Price Action

Last 7 days

15.8%

Last 30 days

-5.2%

Last 90 days

-11.5%

Trailing 12 Months

-13.0%

AKBA RSI Chart

AKBA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKBA Valuation

Market Cap

393.8M

Price/Earnings (Trailing)

-73.67

Price/Sales (Trailing)

1.67

EV/EBITDA

70.72

Price/Free Cashflow

5.82

AKBA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

AKBA Fundamentals

AKBA Revenue

Revenue (TTM)

236.2M

Rev. Growth (Yr)

23.93%

Rev. Growth (Qtr)

-1.95%

AKBA Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

46.31%

Earnings Growth (Qtr)

-2.4K%

AKBA Profitability

Operating Margin

83.29%

EBT Margin

-1.58%

Return on Equity

-16.39%

Return on Assets

-1.42%

Free Cashflow Yield

17.19%

AKBA Investor Care

Shares Dilution (1Y)

13.40%

Diluted EPS (TTM)

-0.02

AKBA Alerts

  • 1 major insider buys and 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025184.9M203.7M225.1M236.2M
2024187.2M174.5M169.9M160.2M
2023271.0M200.6M194.0M194.6M
2022221.0M294.9M294.8M292.7M
2021258.5M221.2M210.0M211.7M
2020350.8M340.2M308.2M294.6M
2019234.5M286.5M325.3M335.0M
2018203.0M223.3M235.2M207.7M
201722.5M51.0M92.2M178.0M
20160001.8M
2015612.2K525.2K410.2K0
2014962.4K875.0K787.6K700.2K
2013001.5M1.0M
20120002.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Akebia Therapeutics Inc

AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEakebia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES204

Akebia Therapeutics Inc Frequently Asked Questions

AKBA is the stock ticker symbol of Akebia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Akebia Therapeutics Inc is 393.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, AKBA's PE ratio (Price to Earnings) is -73.67 and Price to Sales (PS) ratio is 1.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKBA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Akebia Therapeutics Inc has provided -0.16 (multiply by 100 for percentage) rate of return.